Three Articles Highlight Evidence that Anesthesia and Pain Control May Affect Cancer Outcomes
San Francisco, CA. (May 26, 2010) - Women who receive one common pain drug during mastectomy are less likely to develop recurrent breast cancer in the years following surgery, suggests a study in the June issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).
The study adds to a growing body of intriguing but preliminary evidence-outlined in an accompanying research review and editorial-that anesthetic and analgesic drug choices may, through their effects on the immune system, have an impact on the outcomes of cancer surgery.
Ketorolac Linked to Lower Rate of Recurrent Breast Cancer
Dr. Patrice Forget and colleagues of Université Catholique de Louvain, Belgium, assessed possible links between pain medications and recurrent cancer risk in 327 women undergoing mastectomy for breast cancer. Recurrence rates at one to four years after surgery were compared for patients who received different drugs for pain during their surgery.
Women receiving ketorolac-a powerful prescription nonsteroidal anti-inflammatory drug (NSAID), related to aspirin and ibuprofen-seemed to be at lower risk of recurrent breast cancer. The recurrence rate was 6 percent for women who received ketorolac during their mastectomy versus 17 percent for those who did not receive ketorolac. (The overall recurrence rate was 11 percent.)
The lower risk of recurrent cancer was still significant after adjustment for other factors, including the patient’s age and the stage of the cancer. None of the other pain medications used during surgery affected the recurrence rate.
Further Evidence that Anesthetics and Analgesics Could Affect Cancer Risk
It may seem strange that giving a drug for pain could influence the risk of cancer recurrence. Yet the study is only the latest addition to a growing body of evidence suggesting that anesthetic and analgesic (pain-relieving) drugs could affect cancers.
Dr. Antje Gottschalk of University of Virginia, Charlottesville, and colleagues, reviewed the evidence. “A wealth of basic science data supports the hypothesis that the surgical stress response increases the likelihood of cancer dissemination and metastasis during and after cancer surgery,” they write. For example, it has been clearly shown that opioid drugs, such as morphine, inhibit immune responses in humans.
During cancer surgery, cancer cells are released into the bloodstream. Theoretically, the use of drugs that lessen immune responses could reduce the body’s ability to kill these disseminated cancer cells-thus potentially increasing the chances that the cancer could come back. The authors emphasize that there is no evidence showing a link between opioid pain medications and cancer recurrence risk in humans, although “animal data strongly suggest that they may contribute to cancer recurrence.”
There is also evidence of a similar effect of commonly used inhaled anesthetics, according to an accompanying editorial by Dr. James G. Bovill of Leiden University Medical Center. It has even been proposed that reductions in immune system function related to surgical anesthetics could lead these otherwise-dormant cancer cells to become activated.
There are several promising approaches to avoiding the potential effects of anesthetics/analgesics on cancer risk, According to Dr. Gottschalk and colleagues: using regional anesthesia when possible, minimizing doses of opioid drugs, and using NSAIDs that work in the same way as ketorolac. Dr. Bovill emphasizes the need for well-designed scientific trials to prove or disprove the effects of anesthetics and analgesics on recurrent cancer risk. He writes, “Without the results from such studies, we cannot make the informed judgments that will allow us to offer safe anesthesia to our patients while avoiding the devastating consequences of cancer long after the anesthetic has worn off.”
Read the full study in Anesthesia & Analgesia
About the IARS
The International Anesthesia Research Society is a nonpolitical, not-for-profit medical society founded in 1922 to encourage, stimulate, and fund ongoing anesthesia-related research and projects that will enhance and advance the anesthesiology specialty. The IARS has a worldwide membership of 15,000 physicians, physician residents, and others with doctoral degrees, as well as health professionals in anesthesia-related practice. In additional to publishing the monthly scientific journal Anesthesia & Analgesia, the IARS sponsors an annual clinical and scientific meeting, funds anesthesia-related research, and sponsors the Global Perioperative Research Organization (GPRO). Additional information about the society and the journal may be found at www.iars.org and www.anesthesia-analgesia.org.
About Anesthesia & Analgesia
Anesthesia & Analgesia was founded in 1922 and was issued bi-monthly until 1980, when it became a monthly publication. A&A is the leading journal for anesthesia clinicians and researchers and includes more than 500 articles annually in all areas related to anesthesia and analgesia, such as cardiovascular anesthesiology, patient safety, anesthetic pharmacology, and pain management. The journal is published on behalf of the IARS by Lippincott Williams & Wilkins (LWW), a division of Wolters Kluwer Health.
About Lippincott Williams & Wilkins
Lippincott Williams & Wilkins (LWW) is a leading international publisher for healthcare professionals and students with nearly 300 periodicals and 1,500 books in more than 100 disciplines publishing under the LWW brand, as well as content-based sites and online corporate and customer services. LWW is part of Wolters Kluwer Health , a leading provider of information and business intelligence for students, professionals and institutions in medicine, nursing, allied health, pharmacy and the pharmaceutical industry.
Wolters Kluwer Health is a division of Wolters Kluwer, a leading global information services and publishing company. The company provides products and services for professionals in the health, tax, accounting, corporate, financial services, legal, and regulatory sectors. Wolters Kluwer had 2008 annual revenues of €3.4 billion ($4.9 billion), employs approximately 20,000 people worldwide, and maintains operations in over 35 countries across Europe, North America, Asia Pacific, and Latin America. Wolters Kluwer is headquartered in Amsterdam, the Netherlands. Its shares are quoted on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Visit www.wolterskluwer.com for information about our market positions, customers, brands, and organization.
Contacts:
Nancy Lynly
Managing Editor Anesthesia & Analgesia
415-777-2750
nlynly@anesthesia-analgesia.org
Carole Bernstein
Marketing Manager
Lippincott Williams & Wilkins
215-521-8317
carole.bernstein@wolterskluwer.com